Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells

Authors: Ke Jiang, Cuiping Song, Lingkai Kong, Lulu Hu, Guibin Lin, Tian Ye, Gang Yao, Yupeng Wang, Haibo Chen, Wei Cheng, Martin P. Barr, Quentin Liu, Guirong Zhang, Chan Ding, Songshu Meng

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Anaplastic thyroid cancer (ATC) is one of the most aggressive of all solid tumors for which no effective therapies are currently available. Oncolytic Newcastle disease virus (NDV) has shown the potential to induce oncolytic cell death in a variety of cancer cells of diverse origins. However, whether oncolytic NDV displays antitumor effects in ATC remains to be investigated. We have previously shown that the oncolytic NDV strain FMW (NDV/FMW) induces oncolytic cell death in several cancer types. In the present study, we investigated the oncolytic effects of NDV/FMW in ATC.

Methods

In this study, a recombinant NDV expressing green fluorescent protein (GFP) was generated using an NDV reverse genetics system. The resulting virus was named after rFMW/GFP and the GFP expression in infected cells was demonstrated by direct fluorescence and immunoblotting. Viral replication was evaluated by end-point dilution assay in DF-1 cell lines. Oncolytic effects were examined by biochemical and morphological experiments in cultural ATC cells and in mouse models.

Results

rFMW/GFP replicated robustly in ATC cells as did its parent virus (NDV/FMW) while the expression of GFP protein was detected in lungs and spleen of mice intravenously injected with rFMW/GFP. We further showed that rFMW/GFP infection substantially increased early and late apoptosis in the ATC cell lines, THJ-16 T and THJ-29 T and increased caspase-3 processing and Poly (ADP-ribose) polymerase (PARP) cleavage in ATC cells as assessed by immunoblotting. In addition, rFMW/GFP induced lyses of spheroids derived from ATC cells in three-dimensional (3D) cultures. We further demonstrated that rFMW/GFP infection resulted in the activation of p38 MAPK signaling, but not Erk1/2 or JNK, in THJ-16 T and THJ-29 T cells. Notably, inhibition of p38 MAPK activity by SB203580 decreased rFMW/GFP-induced cleavage of caspase-3 and PARP in THJ-16 T and THJ-29 T cells. Finally, both rFMW/GFP and its parent virus inhibited tumor growth in mice bearing THJ-16 T derived tumors.

Conclusion

Taken together, these data indicate that both the recombinant reporter virus rFMW/GFP and its parent virus NDV/FMW, display oncolytic activities in ATC cells in vitro and in vivo and suggest that oncolytic NDV may have potential as a novel therapeutic strategy for ATC.
Appendix
Available only for authorised users
Literature
1.
Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011;2011:542358.CrossRefPubMedPubMedCentral
2.
Bernet V, Smallridge R. New therapeutic options for advanced forms of thyroid cancer. Expert Opin Emerg Drugs. 2014;19(2):225–41.CrossRefPubMed
3.
Hallden G, Portella G. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin Ther Targets. 2012;16(10):945–58.CrossRefPubMed
4.
Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M, Fusco A, Portella G. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology. 2007;148(11):5186–94.CrossRefPubMed
5.
Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R, Hallden G, Portella G. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res. 2008;14(20):6505–14.CrossRefPubMed
6.
Libertini S, Abagnale A, Passaro C, Botta G, Barbato S, Chieffi P, Portella G. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr Relat Cancer. 2011;18(1):129–41.CrossRefPubMed
7.
Passaro C, Volpe M, Botta G, Scamardella E, Perruolo G, Gillespie D, Libertini S, Portella G. PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma. Mol Oncol. 2015;9(1):78–92.CrossRefPubMed
8.
Passaro C, Borriello F, Vastolo V, Di Somma S, Scamardella E, Gigantino V, Franco R, Marone G, Portella G. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget. 2016;7(2):1500–15.CrossRefPubMed
9.
Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Hallden G, Gillespie D, Portella G. Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells. Endocr Relat Cancer. 2013;20(5):633–47.CrossRefPubMed
10.
Reddi HV, Madde P, Reichert-Eberhardt AJ, Galanis EC, Copland JA, McIver B, Grebe SK, Eberhardt NL. ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. Cancer Gene Ther. 2008;15(11):750–7.CrossRefPubMedPubMedCentral
11.
Gholami S, Haddad D, Chen CH, Chen NG, Zhang Q, Zanzonico PB, Szalay AA, Fong Y. Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter. Surgery. 2011;150(6):1040–7.CrossRefPubMed
12.
Mundi N, Um S, Yoo J, Rizzo G, Black M, Pinto N, Palma DA, Fung K, MacNeil D, Mymryk JS, et al. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses. Virus Res. 2014;190:53–9.CrossRefPubMed
13.
Yu Z, Eisenberg DP, Singh B, Shah JP, Fong Y, Wong RJ. Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer. 2004;112(3):525–32.CrossRefPubMed
14.
Huang YY, Yu Z, Lin SF, Li S, Fong Y, Wong RJ. Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab. 2007;92(5):1965–70.CrossRefPubMed
15.
Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab. 2008;93(11):4403–7.CrossRefPubMedPubMedCentral
16.
Price DL, Li P, Chen CH, Wong D, Yu Z, Chen NG, Yu YA, Szalay AA, Cappello J, Fong Y, et al. Silk-elastin-like protein polymer matrix for intraoperative delivery of an oncolytic vaccinia virus. Head & neck. 2016;38(2):237–46.CrossRef
17.
Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC 3rd, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther. 2012;19(9):659–65.CrossRefPubMed
18.
Zamarin D, Martinez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, Garcia-Sastre A, Palese P, Fong Y. Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther. 2009;17(4):697–706.CrossRefPubMedPubMedCentral
19.
Ganar K, Das M, Sinha S, Kumar S. Newcastle disease virus: current status and our understanding. Virus Res. 2014;184:71–81.CrossRefPubMed
20.
Bian J, Wang K, Kong X, Liu H, Chen F, Hu M, Zhang X, Jiao X, Ge B, Wu Y, et al. Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus. Arch Virol. 2011;156(8):1335–44.CrossRefPubMed
21.
Meng S, Zhou Z, Chen F, Kong X, Liu H, Jiang K, Liu W, Hu M, Zhang X, Ding C, et al. Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo. Cancer Lett. 2012;317(1):56–64.CrossRefPubMed
22.
Jiang K, Li Y, Zhu Q, Xu J, Wang Y, Deng W, Liu Q, Zhang G, Meng S. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells. BMC Cancer. 2014;14:551.CrossRefPubMedPubMedCentral
23.
Hu L, Sun S, Wang T, Li Y, Jiang K, Lin G, Ma Y, Barr MP, Song F, Zhang G, et al. Oncolytic Newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. Am J Cancer Res. 2015;5(12):3612–23.PubMedPubMedCentral
24.
Wu Y, Zhang X, Wang X, Wang L, Hu S, Liu X, Meng S. Apoptin enhances the oncolytic properties of Newcastle disease virus. Intervirology. 2012;55(4):276–86.CrossRefPubMed
25.
Marlow LA, D'Innocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL, Wadsworth JT, et al. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J Clin Endocrinol Metab. 2010;95(12):5338–47.CrossRefPubMedPubMedCentral
26.
Song KY, Wong J, Gonzalez L, Sheng G, Zamarin D, Fong Y. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J Mol Med. 2010;88(6):589–96.CrossRefPubMedPubMedCentral
27.
Wei D, Sun N, Nan G, Wang Y, Liu HQ, Peeters B, Chen ZN, Bian H. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Hum Gene Ther. 2012;23(7):700–10.CrossRefPubMed
28.
Guan M, Romano G, Coroniti R, Henderson EE. Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm. J Exp Clin Cancer Res. 2014;33:91.PubMedPubMedCentral
29.
Silberhumer GR, Brader P, Wong J, Serganova IS, Gonen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther. 2010;9(10):2761–9.CrossRefPubMedPubMedCentral
30.
Li P, Chen CH, Li S, Givi B, Yu Z, Zamarin D, Palese P, Fong Y, Wong RJ. Therapeutic effects of a fusogenic Newcastle disease virus in treating head and neck cancer. Head & neck. 2011;33(10):1394–9.CrossRef
31.
Chai Z, Zhang P, Fu F, Zhang X, Liu Y, Hu L, Li X. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer. Virol J. 2014;11:84.CrossRefPubMedPubMedCentral
32.
Bian H, Wilden H, Fournier P, Peeters B, Schirrmacher V. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. Int J Oncol. 2006;29(6):1359–69.PubMed
33.
Buijs PR, van Amerongen G, van Nieuwkoop S, Bestebroer TM, van Run PR, Kuiken T, Fouchier RA, van Eijck CH, van den Hoogen BG. Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy. Cancer Gene Ther. 2014;21(11):463–71.CrossRefPubMed
Metadata
Title
Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells
Authors
Ke Jiang
Cuiping Song
Lingkai Kong
Lulu Hu
Guibin Lin
Tian Ye
Gang Yao
Yupeng Wang
Haibo Chen
Wei Cheng
Martin P. Barr
Quentin Liu
Guirong Zhang
Chan Ding
Songshu Meng
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4522-3

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Validation of Quality of Life Instruments for Cancer Patients – Colorectal Cancer (QLICP-CR) in patients with colorectal cancer in Northeast China

Research article

Detection of mutations in SF3B1, EIF1AX and GNAQ in primary orbital melanoma by candidate gene analysis

Research article

Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis

Research article

Mindfulness-based interventions and cognitive function among breast cancer survivors: a systematic review

Research article

Temporal and geographic variation in the systemic treatment of advanced prostate cancer

Research article

Removal of pectoral muscle based on topographic map and shape-shifting silhouette
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits